
Poplar Therapeutics
Developing a new class of anti-IgE therapy for multiple atopic conditions.
About
Poplar Therapeutics is a biotechnology company focused on developing novel therapies for atopic conditions. Their lead program, PHB-050, is a new class of anti-IgE therapy designed to address a range of allergic diseases.
Listed competitors
Show 6 more similar companies
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Biotech
Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
Shares Biotechnology, Drug Discovery
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to Poplar Therapeutics?
People comparing tools land here. Get listed beside these.
All funding rounds
Tech stack
Detected on poplartx.com, last scanned 30 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Benchmarking
See how your site ranks against 16,849 startups
Poplar Therapeutics sits in the 2nd percentile for Domain Rating. Check where yours lands, free.
Check your Domain RatingPoplar Therapeutics has a Domain Rating of 1, the 2nd percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Bottom 25%
Check yoursAgent Readiness
Below median
Scan yoursSite Speed
Above median
PageSpeedData Trust
Below median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
Poplar Therapeutics scores 40. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentAI visibility
Get read by ChatGPT, Claude and Perplexity
List your startup, then track where you show up in AI answers.
AI reads of this profile
Last 14 days, from server logs
Get notified when Poplar Therapeutics changes
Used Poplar Therapeutics? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is Poplar Therapeutics growing?
Yes, fast. Our data shows it raised $50M in a Series A in January 2026.
Who owns Poplar Therapeutics?
Poplar Therapeutics is privately held, owned by its founders and investors. Investors on record include SR One. Exact stakes are not public.
Are there companies like Poplar Therapeutics?
Yes. We list 7 companies like Poplar Therapeutics, including Novartis (Xolair), Moderna and Epicrispr Biotechnologies.
Is Poplar Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Poplar Therapeutics is 58 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Poplar Therapeutics raised?
Poplar Therapeutics has raised a total of $50M in funding. The most recent round on record is Series A.
How many employees does Poplar Therapeutics have?
Poplar Therapeutics has approximately 15 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Poplar Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch Poplar Therapeutics and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

